# Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert J. Motzer,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,B. Yа. Alekseev,Sun Young Rha,Jaime R. Merchan,Jeffrey C. Goh,Aly‐Khan A. Lalani,Ugo De Giorgi,Bohuslav Melichar,Sung‐Hoo Hong,Howard Gurney,María José Méndez,Evgeny Kopyltsov,Sergei Tjulandin,Teresa Alonso‐Gordoa,Vadim Kozlov,Anna Alyasova,Eric Winquist,Pablo Maroto,Miso Kim,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Karla Rodriguez-Lopez,Joseph E. Burgents,Cixin He,Chinyere E. Okpara,Jodi A. McKenzie,Toni K. Choueiri,for the CLEAR Trial Investigators,Robert J. Motzer,Toni K. Choueiri,Thomas E. Hutson,Luke T. Nordquist,David R. Spigel,Jaime R. Merchan,Saby George,Sandhya Srinivas,Brendan D. Curti,Andrew Pippas,Elisabeth I. Heath,Subramanya Rao,Theodore Stewart Gourdin,Mehmood Hashmi,Nafisa Burhani,Ana M. Molina,Alan J. Koletsky,Robert Alter,C. Alemany,Benjamin A. Gartrell,Mike Cusnir,Harsha Vyas,Stephanie L. Graff,Christian Squillante,Mark Knapp,Ivor Percent,Vijay Patel,Daniel L. Spitz,C. Harkness,Marc Matrana,Lindsay Overton,Stephen Richey,Donald Richards,Habib M. Ghaddar,Robert Galamaga,Ralph J. Hauke,Joseph Haggerty,Ronald Harris,Mark Johns,Samith T. Kochuparambil,Christian Kollmannsberger,Bobby Shayegan,Christina Canil,Eric Winquist,Catherine Sperlich,Georg A. Bjarnason,Naveen S. Basappa,Wolfgang Loidl,Wolfgang Horninger,Manuela Schmidinger,Lionel D’Hondt,Dirk Schrijvers,Annemie Rutten,Peter Schatteman,Wim Wynendaele,Daisy Luyten,Spyridon Sideris,Christine Gennigens,Bohuslav Melichar,Jana Katolická,Jiří Tomášek,Jana Prausová,Tomáš Büchler |
| Citations | 170 |
| DOI | 10.1200/jco.23.01569 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1200/jco.23.01569 |
| OpenAlex ID | https://openalex.org/W4390902638 |
| PMID | 38227898 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Toni K. Choueiri](https://scholariq.org/researchers/toni-k-choueiri/)
- [Masatoshi Eto](https://scholariq.org/researchers/masatoshi-eto/)
- [David R. Spigel](https://scholariq.org/researchers/david-r-spigel/)
- [Takahiro Osawa](https://scholariq.org/researchers/takahiro-osawa/)
- [Yu Nakamura](https://scholariq.org/researchers/yu-nakamura/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.